pharmacokinetics

Converse of object

• alter: Smoking cessation with or without nicotine replacement may alter the pharmacokinetics of certain concomitant medicines.
• affect: Corticosteroids do not appear to affect the pharmacokinetics of infliximab to a clinically relevant extent.
• influence: The authors set out to identify whether levetiracetam, the newest of the anti-epileptic drugs, influences the pharmacokinetics of steroid oral contraceptives.
• regard: Data are insufficient to draw conclusions regarding pharmacokinetics in moderate hepatic impairment.
• exhibit: Topiramate exhibits linear pharmacokinetics with low levels of protein binding.

Preposition: over

range: Irbesartan exhibits linear and dose proportional pharmacokinetics over the dose range of 10 to 600 mg.

Adjective modifier

• linear: Topiramate exhibits linear pharmacokinetics with low levels of protein binding.
• clinical: Analytical expertise also supports experimental and clinical pharmacokinetics, including support for clinical trials involving new drugs at Mount Vernon Hospital and elsewhere.
• altered: Patients with poor renal function may require dosage adjustments due to altered pharmacokinetics of carboplatin.

Noun used with modifier

• population: A population pharmacokinetics analysis was conducted on samples from over 1,100 MS patients receiving doses ranging from 3 to 6 mg/kg natalizumab.
• steady-state: Neurontin steady-state pharmacokinetics are similar for healthy subjects and patients with epilepsy receiving anti-epileptic agents.
• drug: Discuss the influence of clinical characteristics on drug pharmacokinetics.
• dose: This linearity is support for dose -independent pharmacokinetics of digoxin in man.

Preposition: in

patient: To date there have been no specific studies of lamotrigine pharmacokinetics in elderly patients with epilepsy.

Preposition: of

• drug: Little is known about the effect of pregnancy on the pharmacokinetics of new anti-epileptic drugs ( AEDs ).
• atazanavir: Race: a population pharmacokinetic analysis of samples from Phase II clinical trials indicated no effect of race on the pharmacokinetics of atazanavir.
• cinacalcet: The pharmacokinetics of cinacalcet does not change over time.
• aripiprazole: There is no effect of a high fat meal on the pharmacokinetics of aripiprazole.
• alfa: Chronic renal failure patients The pharmacokinetics of darbepoetin alfa has been studied clinically in chronic renal failure patients following intravenous and subcutaneous administration.
• acid: The pharmacokinetics of ibandronic acid was not assessed in patients with end-stage renal disease managed by other than haemodialysis.